神戸大学附属図書館デジタルアーカイブ
https://hdl.handle.net/20.500.14094/90009132

このアイテムのアクセス数:34件（2024-06-13 09:03 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
90009132 (fulltext) pdf 2.07 MB 19

メタデータ

ファイル出力

メタデータID
90009132
アクセス権
open access
出版タイプ
Version of Record
タイトル
Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections
著者
Kurahashi, Yukiya ; Sutandhio, Silvia ; Furukawa, Koichi ; Tjan, Lidya Handayani ; Iwata, Sachiyo ; Sano, Shigeru ; Tohma, Yoshiki ; Ohkita, Hiroyuki ; Nakamura, Sachiko ; Nishimura, Mitsuhiro ; Arii, Jun ; Kiriu, Tatsunori ; Yamamoto, Masatsugu ; Nagano, Tatsuya ; Nishimura, Yoshihiro ; Mori, Yasuko
著者名
Kurahashi, Yukiya
著者名
Sutandhio, Silvia
著者ID
A2762
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=89bc47bdf7481960520e17560c007669
著者名
Furukawa, Koichi
古川, 皓一
フルカワ, コウイチ
所属機関名
医学研究科
著者名
Tjan, Lidya Handayani
著者名
Iwata, Sachiyo
著者名
Sano, Shigeru
著者名
Tohma, Yoshiki
著者名
Ohkita, Hiroyuki
著者名
Nakamura, Sachiko
著者ID
A0486
研究者ID
1000040510285
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=8ba58502605c9ec6520e17560c007669
著者名
Nishimura, Mitsuhiro
西村, 光広
ニシムラ, ミツヒロ
所属機関名
医学研究科
著者ID
A2591
研究者ID
1000030704928
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=1f0aa402893ddbca520e17560c007669
著者名
Arii, Jun
有井, 潤
アリイ, ジュン
所属機関名
医学研究科
著者名
Kiriu, Tatsunori
著者ID
A1538
研究者ID
1000040542139
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=183d9080319b2c1e520e17560c007669
著者名
Yamamoto, Masatsugu
山本, 正嗣
ヤマモト, マサツグ
所属機関名
医学部附属病院
著者ID
A0860
研究者ID
1000080624684
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=a3a21385ba2a8535520e17560c007669
著者名
Nagano, Tatsuya
永野, 達也
ナガノ, タツヤ
所属機関名
医学研究科
著者ID
A0759
研究者ID
1000020291453
著者名
Nishimura, Yoshihiro
西村, 善博
ニシムラ, ヨシヒロ
所属機関名
医学部附属病院
著者ID
A0456
研究者ID
1000050343257
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=11c6b67469a01145520e17560c007669
著者名
Mori, Yasuko
森, 康子
モリ, ヤスコ
所属機関名
医学研究科
収録物名
Frontiers in Immunology
巻(号)
13
ページ
773652
出版者
Frontiers Media
刊行日
2022-02-24
公開日
2022-04-12
抄録
Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the virus responsible for the Coronavirus Disease 2019 (COVID-19) pandemic. The emergence of variants of concern (VOCs) has become one of the most pressing issues in public health. To control VOCs, it is important to know which COVID-19 convalescent sera have cross-neutralizing activity against VOCs and how long the sera maintain this protective activity. Methods: Sera of patients infected with SARS-CoV-2 from March 2020 to January 2021 and admitted to Hyogo Prefectural Kakogawa Medical Center were selected. Blood was drawn from patients at 1-3, 3-6, and 6-8 months post onset. Then, a virus neutralization assay against SARS-CoV-2 variants (D614G mutation as conventional strain; B.1.1.7, P.1, and B.1.351 as VOCs) was performed using authentic viruses. Results: We assessed 97 sera from 42 patients. Sera from 28 patients showed neutralizing activity that was sustained for 3-8 months post onset. The neutralizing antibody titer against D614G significantly decreased in sera of 6-8 months post onset compared to those of 1-3 months post onset. However, the neutralizing antibody titers against the three VOCs were not significantly different among 1-3, 3-6, and 6-8 months post onset. Discussion: Our results indicate that neutralizing antibodies that recognize the common epitope for several variants may be maintained for a long time, while neutralizing antibodies having specific epitopes for a variant, produced in large quantities immediately after infection, may decrease quite rapidly.
キーワード
SARS-CoV-2
COVID-19
variants
neutralization
breadth
カテゴリ
医学研究科
医学部附属病院
学術雑誌論文
権利
© 2022 Kurahashi, Sutandhio, Furukawa, Tjan, Iwata, Sano, Tohma, Ohkita, Nakamura, Nishimura, Arii, Kiriu, Yamamoto, Nagano, Nishimura and Mori.
CC license
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.